Rapport Therapeutics announced in early January 2026 that the FDA has cleared RAP-219 to move into Phase 3 registrational trials for focal onset seizures, while the company advances a broader ...
Rapport Therapeutics, Inc.'s RAP-219 delivered impressive Phase 2a results in drug-resistant focal onset seizures, driving Rapport Therapeutics' stock up over 135% and boosting investor optimism. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results